Hybridoma cell strain capable of secreting dihydrazide compound monoclonal antibody
Through the hybridoma cell lines secreting monoclonal antibodies of bishydrazide compounds, the complexity and cost of bishydrazide detection methods in the prior art are solved, and the rapid and sensitive detection of bishydrazide compounds is achieved. , has practical application value.
Patent Information
- Application Number
- CN202410990845.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-23
AI Technical Summary
The prior art lacks monoclonal antibodies with high specificity and sensitivity to bishydrazide pesticides, which leads to complex and costly detection methods for bishydrazide pesticides, making it difficult to quickly and easily detect residues in agricultural products.
Provide a hybridoma cell line that secretes monoclonal antibodies of bishydrazide compounds. Complete antigens are prepared by hapten and immunized by animals, and obtains monoclonal antibodies with high sensitivity and specificity for enzyme-linked immunosorbent assays ( ELISA) test.
It realizes rapid and sensitive detection of bishydrazide compounds, with IC50 value lower than trace concentration, which has practical application value and can effectively detect trace bishydrazide compounds residues in the sample.
Smart Images

Figure CN119060191A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunochemistry, in particular to a hybridoma cell strain secreting monoclonal antibodies of diacylhydrazide compounds. Background Art
[0002] Bishydrazide pesticides are a type of non-steroidal insect growth regulator, commonly used in agriculture to control lepidopteran larvae. Bishydrazide pesticides include fenbuconazole, chlorhydrazide, methoxyfenozide, chlorfenazolidone, and chlorfenapyr. Although bishydrazide pesticides are considered environmentally friendly insecticides due to their high specificity, their residues in edible agricultural products may pose a potential health risk to humans. Studies have shown that fenbuconazole does not distinguish between insect cells and human cells in terms of cytotoxic effects, and can induce G1 / S cell cycle arrest through the mitochondrial pathway, ultimately leading to cell apoptosis. In order to mitigate the negative impact of fenbuconazole on human health, many countries have established maximum residue limits (MRLs) for its use in agricultural products. In China, the maximum residue limit of tebufenozide ranges from 0.05mg / kg for lily to 20mg / kg for leafy vegetables; the maximum residue limit of methoxyfenozide ranges from 0.02mg / kg for corn to 20mg / kg for dried chili peppers; the maximum residue limit of fenvalerate in cereals is 20mg / kg; the maximum residue limit of chlorfenapyr in cereals is 2mg / kg. Detection of the presence of dihydrazide pesticide residues in agricultural products is crucial to protecting human health.
[0003] At present, the detection method of diacylhydrazide pesticides is mainly instrumental detection, and commonly used methods include high performance liquid chromatography (HPLC), liquid chromatography tandem mass spectrometry (LC-MS / MS), high performance liquid chromatography mass spectrometry (HPLC-MS), and ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS / MS). Although these chromatography-based methods have high sensitivity and specificity, they have some disadvantages, such as the need for thorough sample purification, high solvent consumption, expensive equipment, and skilled technicians. Therefore, a rapid and simple method for detecting diacylhydrazide pesticide residues is needed.
[0004] Enzyme-linked immunosorbent assay (ELISA) is an extremely efficient, sensitive and rapid detection method. It has simple sample pretreatment, few purification steps, large analytical capacity, low detection cost and easy operation. It is suitable for rapid on-site detection of a large number of samples, so it has been widely used in drug residue analysis. The premise of using ELISA to detect diacylhydrazide pesticides is to obtain monoclonal antibodies with high specificity and high sensitivity to diacylhydrazide pesticides. Therefore, it is very important to prepare a monoclonal antibody with high specificity and high sensitivity to diacylhydrazide pesticides. Summary of the invention
[0005] Therefore, the technical problem to be solved by the present invention is to overcome the problem in the prior art of lacking a monoclonal antibody with high specificity and high sensitivity to dihydrazide pesticides.
[0006] In order to solve the above technical problems, the present invention provides a hybridoma cell line that secretes a monoclonal antibody against a dihydrazide compound. The hybridoma cell line was deposited in the General Microbiological Center of the China Microbiological Culture Collection Committee on April 18, 2024, and the deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 45916. The monoclonal antibody secreted by the hybridoma cell line of the present invention has good sensitivity and specificity to dihydrazide compounds, such as fenvalerate, fenvalerate, chlorhydrazide, methoxyfenvalerate, chromafenvalerate, etc., and can efficiently and quickly detect dihydrazide compounds.
[0007] The first object of the present invention is to provide a hybridoma cell strain, which was deposited in the General Microbiology Center of China National Microbiological Culture Collection Committee on April 18, 2024, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No.45916.
[0008] Furthermore, the hybridoma cell line is obtained by immunizing an animal with a complete antigen prepared by a hapten, wherein the structural formula of the hapten is as shown in Formula I:
[0009]
[0010] Furthermore, the complete antigen is obtained by coupling the above hapten to a carrier protein.
[0011] Furthermore, the carrier protein includes keyhole limpet hemocyanin.
[0012] The second object of the present invention is to provide an application of the hybridoma cell line in detecting bisacylhydrazide compounds.
[0013] Furthermore, the dihydrazide compounds include fenvalerate, chlorhydrazide, methoxyfenhydrazide and chlorhydrazide.
[0014] The third object of the present invention is to provide a monoclonal antibody secreted by the hybridoma cell line.
[0015] The fourth object of the present invention is to provide an application of a monoclonal antibody in detecting diacylhydrazide compounds.
[0016] A fifth object of the present invention is to provide a detection product for dihydrazide compounds, wherein the detection product comprises the above-mentioned monoclonal antibody.
[0017] Furthermore, the detection product also includes a coating source.
[0018] Furthermore, the coating is prepared by coupling a hapten to a carrier protein, and the carrier protein includes chicken ovalbumin.
[0019] Beneficial effects of the present invention:
[0020] The monoclonal antibody secreted by the hybridoma cell line of the present invention has high sensitivity and specificity to diacylhydrazide compounds, wherein the IC 50 The value is 0.176ng / mL, and the IC 50 The value is 0.44ng / mL, and the IC value of hydrazine for food inhibition is 50 The value is 2.48ng / mL, and the IC 50 The value is 1.36ng / mL, and the IC 50 The value is 1.68ng / mL, so trace amounts of dihydrazide compounds in the sample can be detected. The present invention provides an immunological method for detecting the content of dihydrazide pesticides in a sample, and has practical application value.
[0021] Biomaterial Deposit
[0022] The monoclonal cell strain Plau was deposited in the General Microbiology Center of China Culture Collection Administration on April 18, 2024, with the deposit number CGMCC No.45916, and the deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein
[0024] Figure 1 This is the standard inhibition curve of monoclonal antibody against bisacylhydrazide compounds. DETAILED DESCRIPTION
[0025] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0026] The culture medium involved in the following examples is as follows:
[0027] RPMI-1640 medium (mg / L): L-arginine 290, L-asparagine 50, L-aspartic acid 20, L-cystine dihydrochloride 65.15, L-glutamic acid 20, glycine 10, L-histidine 15, L-hydroxyproline 20, L-isoleucine 50, L-leucine 50, L-lysine hydrochloride 40, L-methionine 15, L-phenylalanine 15, L-proline 20, L-serine 30, L-threonine 20, L-tryptophan 5, L-tyrosine 23.19, L-valine 20, p-aminobenzoic acid 1, calcium nitrate 100, anhydrous magnesium sulfate 48.84, anhydrous sodium dihydrogen phosphate 676.13, potassium chloride 400, sodium chloride 6000, glucose 2000, reduced glutathione 1, phenol red 5, L-glutamine 300, biotin 0.2, D-calcium pantothenate 0.25, folic acid 1, i-inositol 35, niacinamide 1, choline chloride 3, pyridoxine hydrochloride 1, riboflavin 0.2, thiamine hydrochloride 1, vitamin B12 0.005, sodium bicarbonate 2000.
[0028] The reagents involved in the following examples are as follows:
[0029] Carbonate buffer (CBS): Weigh 1.59 g of Na2CO3 and 2.93 g of NaHCO3, dissolve them in a small amount of double distilled water respectively and mix them, add double distilled water to about 800 mL and mix well, adjust the pH to 9.6, add double distilled water to 1000 mL, and store at 4°C for later use.
[0030] Phosphate buffered saline (PBS): 8.00 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 2.9 g Na2HPO4·12H2O, dissolved in 800 mL pure water, adjusted to pH 7.2-7.4 with NaOH or HCl, and made up to 1000 mL;
[0031] PBST: PBS containing 0.05% Tween 20;
[0032] Antibody diluent: PBS containing 0.1% gelatin;
[0033] TMB colorimetric solution: Solution A: 18.43g Na2HPO4·12H2O, 9.33g citric acid, dilute to 1000mL with pure water; Solution B: 60mg TMB dissolved in 100mL ethylene glycol. Mix solution A and solution B in a ratio of 5:1 to obtain the TMB colorimetric solution, and mix again when using.
[0034] The detection methods involved in the following embodiments are as follows:
[0035] Method for detecting the inhibition rate of dihydrazide compounds: The most suitable antigen and antibody concentrations in ic-ELISA were selected by chessboard test. The antigen was diluted to 0.01, 0.03, 0.1 and 0.3 μg / mL with carbonate buffer (CBS), and the antibody was diluted to 0.03, 0.1, 0.3 and 1 μg / mL with antibody diluent. After selecting the best working point, the dihydrazide compound standard was diluted to 8 concentrations (0, 0.0098, 0.039, 0.156, 0.625, 2.5, 10 and 40 ng / mL), and the ic-ELISA operation steps were followed. Finally, OriginPro 8.5 was used to make the graph (the results are shown in Figure 2). Figure 1 As shown), obtain the standard inhibition curve of bisacylhydrazide compounds and calculate IC 50 .
[0036] Example 1: Synthesis of dihydrazide hapten
[0037] Since the small molecules of dihydrazide compounds are not immunogenic and cannot stimulate mice to produce immune responses and then produce antibodies, the dihydrazide compounds need to be coupled to proteins through protein connection technology to make them immunogenic; the active groups commonly used in protein coupling technology include amino, carboxyl, hydroxyl, thiol, etc., and since the molecular structure of dihydrazide compounds does not contain these active groups, dihydrazide compounds are designed for derivatization.
[0038] Benzoic acid, 3,5-diMethyl-, 1-(1,1-diMethylethyl)hydrazide (CAS: 162752-59-2, 200 mg) was dissolved in DMF (15 mL) and dimethyl terephthalate (100 mg) was slowly added. The resulting mixture was stirred at 75 ° C for 7 h and then concentrated to obtain a light yellow viscous substance. It was treated with water and extracted with ethyl acetate, then dried over NaSO4, concentrated on a rotary evaporator, and purified on a silica gel column to obtain a light yellow solid. The light yellow solid was dissolved in anhydrous methanol (20 mL) at 25 ° C, and NaOH (2M, 20 mL) was slowly added, stirred for 10 min and allowed to warm to 45 ° C overnight. The mixture was filtered through a celite pad and the solid was rinsed with ethyl acetate. The filtrate was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (100 mL) and washed with water (3×100 mL) and brine (100 mL) in sequence. The organic layer was separated, dried over sodium sulfate, filtered and concentrated in vacuo to afford the bisacylhydrazide hapten of formula I (60 mg, 8%).
[0039]
[0040] Example 2: Synthesis of complete antigen of bishydrazide compound
[0041] Weigh 6 mg of dihydrazide hapten and 4.4 mg of N-hydroxysuccinimide (NHS), dissolve in 200 μL of N,N-dimethylformamide (DMF), stir at room temperature for 10 min; then weigh 7.5 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), add to the dihydrazide hapten solution, stir at room temperature for 6-8 h, and activate. Take 6 mg of keyhole limpet hemocyanin (KLH), add to 3 mL of 0.01 M carbonate buffer (CBS), fully dissolve, slowly add the activated hapten to the diluent in which KLH is dissolved, and stir at room temperature overnight. Then dialyze with 0.01 M PBS solution to remove unreacted small molecules, obtain a relatively pure complete antigen, and identify it by ultraviolet absorption scanning method.
[0042] Example 3: Synthesis of Bisacylhydrazide Compound Coating
[0043] 3.2 mg of dihydrazide hapten and 2.4 mg of N-hydroxysuccinimide (NHS) were dissolved in 200 μL of anhydrous N,N-dimethylformamide (DMF) and stirred at room temperature for 10 min; 4.2 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was dissolved in the above solution and stirred at room temperature for 6-8 h to obtain hapten activation solution; 6 mg of chicken ovalbumin (OVA) was dissolved in carbonate buffer (CBS); the hapten activation solution was slowly added to the protein diluent and stirred at room temperature overnight. Then, the reaction solution was dialyzed with 0.01 M PBS solution to remove unreacted small molecules to obtain the coating source.
[0044] Example 4: Preparation of hybridoma cell lines secreting monoclonal antibodies to bisacylhydrazide compounds
[0045] (1) Acquisition of animal immunity
[0046] After the complete antigen of the dihydrazide compound was mixed and emulsified with an equal amount of Freund's adjuvant, BALB / c mice were immunized by multiple subcutaneous injections at the back of the neck (except for sprint immunization); the first immunization used complete Freund's adjuvant, with a dose of 100 μg / mouse; multiple booster immunizations used incomplete Freund's adjuvant and the dose was halved to 50 μg / mouse; sprint immunizations used no adjuvant, and were directly diluted with physiological saline and injected intraperitoneally, and the dose was halved again to 25 μg / mouse; the first immunization and the second booster immunization were separated by one month, the multiple booster immunizations were separated by 21 days, and the sprint immunization and the last booster immunization were separated by 18-21 days; the immune effect of mice was observed by indirect competitive enzyme-linked immunosorbent assay (ic-ELISA), that is, the titer and inhibition of mouse serum were detected;
[0047] (2) Cell fusion
[0048] Three days after the sprint immunization, cell fusion was performed according to the conventional PEG (polyethylene glycol, molecular weight 4000) method. The specific steps are as follows:
[0049] a. Cut off the tail to collect blood. After killing the mice by cervical dislocation, immediately put them in 75% alcohol for disinfection and soak for about 5 minutes. Take out the spleen of the mice aseptically, grind them moderately with the rubber tip of the syringe and pass them through a 200-mesh cell sieve to obtain a spleen cell suspension, collect them, centrifuge them (1200rpm, 8min), wash the spleen cells three times with RPMI-1640 medium, dilute the spleen cells to a certain volume after the last centrifugation, count them, and set aside;
[0050] b. Collect SP2 / 0 cells: 7-10 days before fusion, SP2 / 0 tumor cells were amplified in RPMI-1640 medium containing 10% FBS (fetal bovine serum) in a 5% CO2 incubator. Before fusion, the number of SP2 / 0 tumor cells was required to reach 1-4×10 7 , ensure that SP2 / 0 tumor cells are in the logarithmic growth phase before fusion. When fusion occurs, tumor cells are collected, suspended in RPMI-1640 basal culture medium, and cell counts are performed;
[0051] c. Fusion process 7min: In the first minute, 1mL of PEG 4000 was added to the cells from slow to fast; in the second minute, it was allowed to stand; in the third and fourth minutes, 1mL of RPMI-1640 medium was added within 1min; in the fifth and sixth minutes, 2mL of RPMI-1640 medium was added within 1min; in the seventh minute, 1mL of RPMI-1640 medium was added every 10s. Except for the second minute, the solution was shaken continuously at other times. Then, it was warmed at 37℃ for 5min; centrifuged (800rpm, 8min), the supernatant was discarded, and the cell was resuspended in RPMI-1640 screening culture medium containing 20% fetal bovine serum and 2% 50×HAT, and added to a 96-well cell plate at 200μL / well, and cultured in a 37℃, 5% CO2 incubator.
[0052] (3) Cell screening and cell line establishment
[0053] On the third day after cell fusion, the fused cells were half-changed with RPMI-1640 screening medium, and on the fifth day, the medium was fully replaced with RPMI-1640 transition medium containing 20% fetal bovine serum and 1% 100×HT. On the seventh day, the cell supernatant was taken for screening.
[0054] The screening is divided into two steps: the first step is to screen out the positive cell wells by the ic-ELISA method, and the second step is to select dihydrazide compounds as standard products and use the ic-ELISA method to measure the inhibitory effect on the positive cells.
[0055] The cell wells with better inhibition of the bisacylhydrazide compound standard were selected and subcloned by the limiting dilution method. The cells were tested by the same method seven days later.
[0056] Subcloning was performed at least three times according to the above method to finally obtain a cell line of monoclonal antibody against bisacylhydrazide compounds.
[0057] Example 5: Preparation and identification of monoclonal antibodies against bisacylhydrazide compounds
[0058] 8-10 week old BALB / c mice were taken and each mouse was intraperitoneally injected with 1 mL of sterile paraffin oil. Seven days later, each mouse was intraperitoneally injected with 1×10 6 For the bisacylhydrazide hybridoma cells, ascites was collected from the seventh day and the antibodies were purified by the caprylic acid-saturated ammonium sulfate method.
[0059] Under slightly acidic conditions, octanoic acid can precipitate other impurities in the ascites except IgG immunoglobulin, and then centrifuge and discard the precipitate; then use an equal amount of saturated ammonium sulfate solution to precipitate IgG type monoclonal antibodies, centrifuge, discard the supernatant, dissolve with 0.01M PBS solution (pH7.4), dialyze and desalt, and finally obtain the purified monoclonal antibody and store it at -20°C.
[0060] Using indirect competitive ELISA, monoclonal antibodies against diacylhydrazide compounds were detected, which had good detection sensitivity (IC 50 The values were 0.176ng / mL, 0.44ng / mL, 2.48ng / mL, 1.36ng / mL, and 1.68ng / mL, respectively), which can be used for immunoassay detection of diacylhydrazide compounds.
[0061] Cross-reaction experiments were conducted on dihydrazide compounds and their structural analogs (benzoylhydrazide, p-aminohippuric acid, 4-biphenylcarboxylic acid hydrazide). The cross-reaction rate was calculated as follows: Cross-reaction rate (%) = (tebufenozide IC 50 ) / (analog IC 50 )×100%. The experimental results obtained are: the absorbance values in each well of the ELISA plate corresponding to benzoylhydrazide, p-aminohippuric acid, and 4-biphenylcarboxylic acid hydrazide have no significant difference with the change of the dilution concentration of the standard, and the specific results are shown in Table 1. This result shows that the cross-reaction rate of the monoclonal antibody to other structural analogs is very low, and it has good specificity for fenbufenozide, methoxyfenbufenozide, fenbufenozide, chlorfenapyr, and chlorfenapyr.
[0062] Table 1 Cross-reaction results of bisacylhydrazide compounds and their structural analogs
[0063]
[0064]
[0065] Example 6: Application of monoclonal antibodies against bisacylhydrazide compounds
[0066] The monoclonal antibody prepared by hybridoma cell line through ascites in vivo was applied to the ELISA addition recovery test of bisacylhydrazide compounds. The specific steps are as follows:
[0067] Coat a 96-well ELISA plate with 0.1 μg / mL of the coating agent diluted with carbonate buffer (CBS), 100 μL per well, bake at 37°C for 2 h, wash the plate three times with PBST solution, 200 μL per well each time, 3 min each time, and pat dry;
[0068] Block with CBS containing 0.2% gelatin, 200 μL per well, bake at 37°C for 2 h, wash the plate three times with PBST, 200 μL per well each time, 3 min each time, and pat dry;
[0069] Use phosphate buffered saline (PBS) to prepare 0, 0.037, 0.111, 0.333, 1, 3, 9 and 27 ng / mL of diacylhydrazide compound standard solutions, respectively. Add the standard solutions and the sample extracts to be tested to the blocked ELISA plate, 50 μL per well, repeat 3 wells for each sample, then add 50 μL of diacylhydrazide compound monoclonal antibody diluted to 0.1 μg / mL to each well, react at 37°C for 30 min, wash the plate and pat dry;
[0070] 100 μL of HRP-labeled goat anti-mouse IgG secondary antibody diluted 1:3000 in PBS containing 0.1% gelatin was added to each well, reacted at 37°C for 30 min, and the plate was washed and patted dry;
[0071] Add 100 μL of TMB colorimetric solution to each well, develop at 37°C for 15 min, then add 50 μL of 2M H2SO4 stop solution to each well, and measure the absorbance at 450 nm;
[0072] Add recovery and sample pretreatment: Select rice as the test sample. After the sample is crushed, pass it through a 20-mesh standard sieve. Weigh three samples, each 20 g, and add 5 ppb, 10 ppb, and 20 ppb of diacylhydrazide compound standards to the samples (according to the linear range of the antibody and IC 50Set the added concentration), add 10mL of water and vortex mix, let stand for 30min, and filter. Add 50mL of acetone to the sample, shake on an electric shaker for 30min, filter into a beaker with a rapid qualitative filter paper, extract the residue once with 30mL of acetone according to the above method, wash the residue twice with 30mL of acetone, add the washing liquid into the beaker, concentrate to near dryness in a 50℃ water bath, and re-dissolve with 5mL of 10% acetone PBS solution (i.e., dilute five times to reduce the influence of the sample matrix).
[0073] Indirect competitive ELISA was used to conduct the recovery test, and the recovery rates were 96%-104% for fenbumidazole, 98.3%-113% for methoxyfenbumidazole, 93.8%-102.8% for fenbumidazole, 97%-105% for chromatofenbumidazole, and 97.3%-112% for chlorfenapyr.
[0074] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A hybridoma cell line, characterized in that The hybridoma cell line was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on April 18, 2024, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No.45916.
2. The hybridoma cell line according to claim 1, characterized in that The hybridoma cell line is obtained by immunizing an animal with a complete antigen prepared by a hapten, wherein the structural formula of the hapten is shown in Formula I:
3. The hybridoma cell line according to claim 2, characterized in that The complete antigen is obtained by coupling the hapten to a carrier protein.
4. The hybridoma cell line according to claim 3, characterized in that The carrier protein includes keyhole limpet hemocyanin.
5. Use of the hybridoma cell line according to any one of claims 1 to 4 in detecting bisacylhydrazide compounds.
6. A monoclonal antibody secreted by the hybridoma cell line according to any one of claims 1 to 4.
7. Use of the monoclonal antibody according to claim 6 in detecting diacylhydrazide compounds.
8. A detection product for dihydrazide compounds, characterized in that: The detection product comprises the monoclonal antibody according to claim 6.
9. The detection product according to claim 8, characterized in that: The detection product also includes a coating source.
10. The detection product according to claim 9, characterized in that: The coating source is prepared by coupling hapten with carrier protein; the carrier protein includes chicken ovalbumin.
Citation Information
Patent Citations
Nifuroxazide hapten, nifuroxazide artificial antigen, preparation method of artificial antigen and application of nifuroxazide hapten and artificial antigen
CN110642743A
Hybridoma cell strain secreting dimethomorph monoclonal antibody and application of hybridoma cell strain
CN113621583A
Tebufenozide hapten, tebufenozide antigen, tebufenozide antibody, tebufenozide detection device and preparation and application thereof
CN116082185A
